PDS Biotechnology (PDSB) investor relations material

Company overview and business model

• Clinical-stage immunotherapy company focused on targeted cancer and infectious disease therapies using proprietary Versamune® and Infectimune® T cell activators, and PDS01ADC, an IL-12 antibody drug conjugate.

• Versamune® platform aims to convert immune-suppressive tumors to immunogenic environments and induce potent CD8 T cell responses.

• Infectimune® is designed for preventive vaccines, promoting both T cell and neutralizing antibody responses.

• Proprietary combinations with checkpoint inhibitors or standards of care are intended to enhance anti-tumor efficacy.

Financial performance and metrics

• As of April 23, 2026, public float was approximately $73.99 million, with 54,404,262 shares held by non-affiliates at $1.36 per share.

• Last reported sale price of common stock on April 23, 2026, was $0.9281 per share.

• No securities sold under General Instruction I.B.6 of Form S-3 in the prior 12 months.

Use of proceeds and capital allocation

• Net proceeds intended for further development and commercialization of product candidates and general corporate purposes, including reducing debt, acquisitions, licensing, stock repurchases, capital expenditures, and working capital.

• Management retains broad discretion over allocation and timing of expenditures.